We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-13.06%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.87B
AUM Growth
-$516M
Cap. Flow
-$33.5M
Cap. Flow %
-1.79%
Top 10 Hldgs %
48.99%
Holding
144
New
7
Increased
8
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$45.3M
2
FATE icon
Fate Therapeutics
FATE
+$16.6M
3
CYTK icon
Cytokinetics
CYTK
+$11.1M
4
SNTI icon
Senti Biosciences Holdings
SNTI
+$4.46M
5
WVE icon
Wave Life Sciences
WVE
+$3.85M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$60.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$18.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
5
BLU
BELLUS Health Inc.
BLU
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.18%
2 Consumer Discretionary 5.28%
3 Financials 0.87%
4 Consumer Staples 0.28%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APTX
76
DELISTED
Aptinyx Inc. Common Stock
APTX
$3.41M 0.18%
6,116,493
– –
STOK icon
77
Stoke Therapeutics
STOK
$1.84B
$3.3M 0.18%
250,000
– –
IVVD icon
78
Invivyd
IVVD
$160M
$3.28M 0.18%
1,000,000
– –
CGEM icon
79
Cullinan Oncology
CGEM
$1.06B
$3.21M 0.17%
250,000
– –
RUBY
80
DELISTED
Rubius Therapeutics, Inc
RUBY
$3.15M 0.17%
3,701,580
– –
HOOK
81
DELISTED
HOOKIPA Pharma
HOOK
$3.02M 0.16%
184,962
– –
PRAX icon
82
Praxis Precision Medicines
PRAX
$8.11B
$2.94M 0.16%
80,000
– –
VIGL
83
DELISTED
Vigil Neuroscience
VIGL
$2.89M 0.15%
1,121,191
– –
MIR icon
84
Mirion Technologies
MIR
$3.56B
$2.88M 0.15%
500,000
– –
VOR icon
85
Vor Biopharma
VOR
$1.06B
$2.73M 0.15%
27,500
– –
CINC
86
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$2.58M 0.14%
+137,010
New +$2.62M
SANA icon
87
Sana Biotechnology
SANA
$882M
$2.57M 0.14%
400,000
– –
IMUX icon
88
Immunic
IMUX
$178M
$2.43M 0.13%
70,000
– –
ZYME icon
89
Zymeworks
ZYME
$1.62B
$2.38M 0.13%
450,000
– –
BBIO icon
90
BridgeBio Pharma
BBIO
$16.4B
$2.27M 0.12%
250,000
– –
TCRR
91
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$2.17M 0.12%
750,000
– –
TIL icon
92
Instil Bio
TIL
$49M
$2.08M 0.11%
22,500
– –
SNTI icon
93
Senti Biosciences Holdings
SNTI
$10.8M
$2.07M 0.11%
105,556
+55,556
+111% +$4.46M
ADAG
94
Adagene
ADAG
$246M
$2.07M 0.11%
1,000,000
– –
IMMP
95
Immutep
IMMP
$56.1M
$2.03M 0.11%
1,000,000
– –
YI
96
111 Inc
YI
$31.3M
$1.99M 0.11%
96,635
– –
NEXI
97
DELISTED
NexImmune, Inc. Common Stock
NEXI
$1.93M 0.1%
48,000
– –
LENZ
98
LENZ Therapeutics
LENZ
$179M
$1.93M 0.1%
100,000
– –
HARP
99
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$1.91M 0.1%
100,000
– –
FUSN
100
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$1.87M 0.1%
750,000
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2022 Portfolio in Review

As of Q2 2022, Artal Group held 144 positions worth $1.87B, down 22% from $2.39B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Artal Group's Q2 2022 filing shows 7 new, 8 increased, 8 reduced and 9 closed positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M. The largest sale was argenx, an estimated $60.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q2 2022 buy was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M.
  • Artal Group added most to Scholar Rock in Q2 2022, an estimated $45.3M increase.
  • Artal Group's biggest Q2 2022 reduction was argenx, cutting an estimated $60.4M.
  • Artal Group fully exited Protagonist Therapeutics in Q2 2022, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 49% of its $1.87B portfolio in Q2 2022.
  • Artal Group opened 7 new positions and closed 9 in Q2 2022.
  • Artal Group's portfolio value fell 22% quarter-over-quarter to $1.87B.

Based on Artal Group's 13F filing for Q2 2022, filed 11 Aug 2022.